Market Place
Sourcing Support
Zcube Announces 5 Startups For New Edition Focused Women`s Health
10 Oct 2024 //
PRESS RELEASE
Zambon Ventures Leads C$2 million investment In Health Innovation
24 Sep 2024 //
PRESS RELEASE
Zambon Phase 3 Study Shows Success In CMS I-neb Efficacy In NCFB
13 Sep 2024 //
PRESS RELEASE
Giovanni Magnaghi is the new Chief Executive Officer of Zambon SpA
02 May 2024 //
PRESS RELEASE
Zcube Launches 2024 Open Accelerator For Life Sciences Startups Focusing On Women`s Health
27 Feb 2024 //
PRESS RELEASE
Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 2024 //
PRESS RELEASE
Zambon Shares Phase 3 PROMIS Studies Results Of CMS I-neb At Bronchiectasis Conference
18 Jul 2023 //
PRESS RELEASE
Zambon Presents Results Showcasing Impact of Bronchiolitis Obliterans Syndrome
23 May 2023 //
PRESS RELEASE
Zambon Announces Data Highlighting Lifetime Burden of Illness in BOS
09 May 2023 //
PRESS RELEASE
Zambon Completes Enrollment in Phase 3 Development Program Evaluating L-CsA-i
02 May 2023 //
PRESS RELEASE
Zambon and IMA Active: paving the way towards process optimisation
23 Nov 2022 //
PHARMACEUTICAL MANUFACTURER
Zambon to Attend the CHEST Annual Meeting 2022
14 Oct 2022 //
PR NEWSWIRE
Zambon Announces Attendance at American Thoracic Society 2022 Annual Meeting
12 May 2022 //
PR NEWSWIRE
Zambon to present data on lung transplantation trends & survival rates in Europe
26 Apr 2022 //
PR NEWSWIRE
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb®
21 Apr 2022 //
PRESS RELEASE
Near Angers. Strike at Zach system in Avrillé, the Seveso-classified factory
07 Mar 2022 //
OUEST FRANCE
COVID-19. A probiotic formula reduces symptom duration and viral load
21 Feb 2022 //
PRESS RELEASE
Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients
08 Sep 2021 //
PRESS RELEASE
Newron & Zambon sign agreement for potentially pivotal study with safinamide
12 May 2021 //
PRESS RELEASE
On the World Parkinson’s Day, Zambon announces Synapses study’s results
12 Apr 2021 //
PRESS RELEASE
Newron & Zambon sign agreement for potentially pivotal study with safinamide
15 Mar 2021 //
PRESS RELEASE
The importance of protecting the lungs from oxidative stress for COPD patients
19 Nov 2020 //
PRESS RELEASE
Zambon at MDS 2020 Virtual Congress
12 Sep 2020 //
PRESS RELEASE
Zambon at ERS2020 Congress
09 Sep 2020 //
PRESS RELEASE
A new FDA Fast Track designation for Zambon
28 Apr 2020 //
PRESS RELEASE
Zambon entered in an exclusive license agreement to register and commercialize riluzole Oral Film in Europe for ALS
13 Nov 2019 //
PRESS RELEASE
Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences
16 Oct 2019 //
PRESS RELEASE
Dipharma Francis S.r.l. Announces Changes in the Leadership Positions
03 Sep 2019 //
BUSINESSWIRE
Zambon completes transformational acquisition of Breath Therapeutics
25 Jul 2019 //
PRESS RELEASE
Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets)
11 Jul 2019 //
PRESS RELEASE
Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide)
15 Jan 2019 //
PRESS RELEASE
Zambon announces approval and ARTG listing of Safinamide in Australia
30 Nov 2018 //
PRESS RELEASE
AstraZeneca and Zambon Announce a Strategic Partnership at CIIE
13 Nov 2018 //
PRESS RELEASE
Xadago® (Safinamide) Now Available In The U.S. For Parkinson’S Disease Patients
31 Jul 2017 //
PRESS RELEASE
Valeo Pharma and Zambon form partnership for Parkinson’s Disease
11 Apr 2017 //
PRESS RELEASE
Zambon Launches Xadago® In Portugal For Patients With Mid- To Late-Stage
10 Apr 2017 //
PRESS RELEASE
Fda Approves Xadago® (Safinamide) For Parkinson’S Disease (Pd) Patients
21 Mar 2017 //
PRESS RELEASE
Seqirus and Zambon enter into a partnership for Parkinson’s disease product
10 Jan 2017 //
PRESS RELEASE
Agreement Zambon -(FIS) for the development of the Lonigo plant
02 Nov 2016 //
PRESS RELEASE
